references

Annual Report 2015 - DNDi (82/92)

Annual Report 2015 - DNDi - (1/92)
Annual Report 2015 - DNDi - (2/92)
Annual Report 2015 - DNDi - (3/92)
Annual Report 2015 - DNDi - VISION, MISSION & STRATEGY (4/92)
Annual Report 2015 - DNDi - (5/92)
Annual Report 2015 - DNDi - (6/92)
Annual Report 2015 - DNDi - (7/92)
Annual Report 2015 - DNDi - (8/92)
Annual Report 2015 - DNDi - (9/92)
Annual Report 2015 - DNDi - (10/92)
Annual Report 2015 - DNDi - (11/92)
Annual Report 2015 - DNDi - (12/92)
Annual Report 2015 - DNDi - (13/92)
Annual Report 2015 - DNDi - R&D MODEL & PORTFOLIO (14/92)
Annual Report 2015 - DNDi - (15/92)
Annual Report 2015 - DNDi - (16/92)
Annual Report 2015 - DNDi - (17/92)
Annual Report 2015 - DNDi - (18/92)
Annual Report 2015 - DNDi - (19/92)
Annual Report 2015 - DNDi - (20/92)
Annual Report 2015 - DNDi - (21/92)
Annual Report 2015 - DNDi - (22/92)
Annual Report 2015 - DNDi - (23/92)
Annual Report 2015 - DNDi - (24/92)
Annual Report 2015 - DNDi - (25/92)
Annual Report 2015 - DNDi - (26/92)
Annual Report 2015 - DNDi - (27/92)
Annual Report 2015 - DNDi - (28/92)
Annual Report 2015 - DNDi - (29/92)
Annual Report 2015 - DNDi - (30/92)
Annual Report 2015 - DNDi - (31/92)
Annual Report 2015 - DNDi - (32/92)
Annual Report 2015 - DNDi - (33/92)
Annual Report 2015 - DNDi - (34/92)
Annual Report 2015 - DNDi - (35/92)
Annual Report 2015 - DNDi - (36/92)
Annual Report 2015 - DNDi - (37/92)
Annual Report 2015 - DNDi - (38/92)
Annual Report 2015 - DNDi - (39/92)
Annual Report 2015 - DNDi - (40/92)
Annual Report 2015 - DNDi - (41/92)
Annual Report 2015 - DNDi - (42/92)
Annual Report 2015 - DNDi - (43/92)
Annual Report 2015 - DNDi - (44/92)
Annual Report 2015 - DNDi - (45/92)
Annual Report 2015 - DNDi - (46/92)
Annual Report 2015 - DNDi - (47/92)
Annual Report 2015 - DNDi - (48/92)
Annual Report 2015 - DNDi - (49/92)
Annual Report 2015 - DNDi - (50/92)
Annual Report 2015 - DNDi - (51/92)
Annual Report 2015 - DNDi - (52/92)
Annual Report 2015 - DNDi - (53/92)
Annual Report 2015 - DNDi - (54/92)
Annual Report 2015 - DNDi - (55/92)
Annual Report 2015 - DNDi - STRENGTHENING EXISTING CAPACITIES (56/92)
Annual Report 2015 - DNDi - (57/92)
Annual Report 2015 - DNDi - (58/92)
Annual Report 2015 - DNDi - (59/92)
Annual Report 2015 - DNDi - (60/92)
Annual Report 2015 - DNDi - (61/92)
Annual Report 2015 - DNDi - ADVOCACY, COMMUNICATIONS & FUNDRAISING (62/92)
Annual Report 2015 - DNDi - (63/92)
Annual Report 2015 - DNDi - (64/92)
Annual Report 2015 - DNDi - (65/92)
Annual Report 2015 - DNDi - (66/92)
Annual Report 2015 - DNDi - (67/92)
Annual Report 2015 - DNDi - FINANCIAL REPORT (68/92)
Annual Report 2015 - DNDi - (69/92)
Annual Report 2015 - DNDi - (70/92)
Annual Report 2015 - DNDi - (71/92)
Annual Report 2015 - DNDi - (72/92)
Annual Report 2015 - DNDi - (73/92)
Annual Report 2015 - DNDi - (74/92)
Annual Report 2015 - DNDi - (75/92)
Annual Report 2015 - DNDi - (76/92)
Annual Report 2015 - DNDi - (77/92)
Annual Report 2015 - DNDi - (78/92)
Annual Report 2015 - DNDi - (79/92)
Annual Report 2015 - DNDi - (80/92)
Annual Report 2015 - DNDi - (81/92)
Annual Report 2015 - DNDi - (82/92)
Annual Report 2015 - DNDi - (83/92)
Annual Report 2015 - DNDi - (84/92)
Annual Report 2015 - DNDi - (85/92)
Annual Report 2015 - DNDi - (86/92)
Annual Report 2015 - DNDi - (87/92)
Annual Report 2015 - DNDi - (88/92)
Annual Report 2015 - DNDi - (89/92)
Annual Report 2015 - DNDi - (90/92)
Annual Report 2015 - DNDi - (91/92)
Annual Report 2015 - DNDi - (92/92)

FINANCIAL REPORT 8 EXPENDITURE a) R&D projects related expenditure Recognized in (Expressed in EUR) 2015 330,026 248,622 16,295 20,279 536,953 1,152,176 (2) 2014 386,214 698,075 57,259 96,869 659,246 143,790 2,041,453 IMPLEMENTATION PROJECT ASAQ - Fixed-dose Artesunate - Amodiaquine (Malaria) (1) ASMQ - Fixed-dose Artesunate - Mefloquine (Malaria)(1) NECT - Nifurtimox - Eflornithine co-administration for stage 2 (HAT) (4) SSG & Paromomycin Combination Therapy for VL in Africa New VL treatments in Asia(3) Paediatric Benznidazole (Chagas) TOTAL IMPLEMENTATION PROJECTS DEVELOPMENT PROJECTS (PHASE IIB/III; REGISTRATION) Fexinidazole (HAT)(4) New VL treatments for Bangladesh New VL treatments in Latin America Coinfection HIV / Visceral Leishmaniasis TOTAL DEVELOPMENT PROJECTS (5) 7,447,957 111,936 684,752 8,244,645 5,843,148 205,824 110,517 698,094 6,857,581 TRANSLATION PROJECTS (PRE-CLINICAL; PHASE I; PHASE IIA/POC) Fexinidazole (Chagas)(6) Oxaborole SCYX-7158 (HAT)(7) Combination Fexinidazole/Miltefosine (VL) Anfoleish (CL)(8) CL Combination (9) CpG-D35 (CL) (10) + PKDL (11) Azoles E1224 (Chagas) New Combination including New Benz Regimen (Chagas) Biomarkers (Chagas)(13) Paediatric HIV ("4-in-1" LPV/r based fixed-dose combination & Superbooster T. b./HIV) (14) Nitroimidazole (VL-2098) + VL 0690 (15) Flubendazole Macrofilaricide (Filaria)(16) Emodepside Macrofilaricide (Filaria)(17) Oxfendazole Macrofilaricide (Filaria) TylAMac Macrofilaricide (Filaria)(19) TOTAL TRANSLATION PROJECTS (18) (12) (2) 640,021 1,258,789 1,693,469 405,377 93,564 318,472 431,643 572,133 2,240,641 515,882 123,618 1,584,830 19,007 323,758 10,221,204 1,212,669 1,236,612 1,252,599 350,718 216,251 46,892 268,908 1,131,282 1,078,126 808,472 938,583 58,828 0 0 8,599,939 RESEARCH PROJECTS (SCREEN; HIT TO LEAD; LEAD OPTIMIZATION) Lead Optimization Consortia(20) Screening Resources & Reference Screening Centres Screening Filaria (22) TOTAL RESEARCH PROJECTS Project-related variable expenditure HCV, Mycetoma, and Anti-infective Chagas Access (23) R&D Coordination & Supervision(24) TOTAL OF PROJECTS RELATED EXPENDITURE 618,048 228,753 4,320,562 32,708,277 187,268 0 3,109,458 27,646,111 (21) 5,614,961 1,333,656 974,272 7,922,889 4,667,142 1,359,345 823,924 6,850,411 82 › DNDi Annual Report 2015